Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community
- Date 2 Aug 2021
Cambridge University spin-out, Qkine, and Enantis, a biotechnology spin-off company from Masaryk University, have concluded a licensing deal for Qkine to use Enantis’s patented FGF2-STAB® technology globally and develop new product-lines based on the unique biochemical properties of the protein.
FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. This optimised form of the protein does not degrade in culture media leading to a range of applications in enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.
You might also be interested in these articles
Steaming up Success: ARU student’s path from café to creativity
We recently did a Q&A session with Anglia Ruskin student Soorya Jith, who started his journey as a Barista at the Lakeside Café within the Bradfield Centre on Cambridge Science Park. He has now transitioned to Krank, also located on the Park, as a Junior Graphic Designer.
Sun 21 Apr 2024
Cambridge Science Park
Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors
Leading DeepTech Venture-Builder Further Strengthens its Unique Position to Cultivate Innovative Technologies with the Addition of Seasoned Industry Professionals
Sun 14 Apr 2024
Cambridge Future Tech
Xampla welcomes former P&G chemist to team as scale-up accelerates
accelerates CREATOR of plastic-free, natural materials, Xampla, continues to scale-up the commercialisation of its biodegradable Morro materials with new industry hire.
Fri 1 Mar 2024
Xampla Ltd
